4.5 Review

Sex differences in autoimmune disorders of the central nervous system

Journal

SEMINARS IN IMMUNOPATHOLOGY
Volume 41, Issue 2, Pages 177-188

Publisher

SPRINGER HEIDELBERG
DOI: 10.1007/s00281-018-0723-8

Keywords

-

Funding

  1. Landesforschungsforderung Hamburg [LFF-FV 45]

Ask authors/readers for more resources

Stronger adaptive immune responses in females can be observed in different mammals, resulting in better control of infections compared to males. However, this presumably evolutionary difference likely also drives higher incidence of autoimmune diseases observed in humans. Here, we summarize sex differences in the most common autoimmune diseases of the central nervous system (CNS) and discuss recent advances in the understanding of possible underlying immunological and CNS intrinsic mechanisms. In multiple sclerosis (MS), the most common inflammatory disease of the CNS, but also in rarer conditions, such as neuromyelitis optica spectrum disorders (NMOSD) or neuronal autoantibody-mediated autoimmune encephalitis (AE), sex is one of the top risk factors, with women being more often affected than men. Immunological mechanisms driving the sex bias in autoimmune CNS diseases are complex and include hormonal as well as genetic and epigenetic effects, which could also be exerted indirectly via modulation of the microbiome. Furthermore, CNS intrinsic differences could underlie the sex bias in autoimmunity by differential responses to injury. The strong effects of sex on incidence and possibly also activity and progression of autoimmune CNS disorders suggest that treatments need to be tailored to each sex to optimize efficacy. To date, however, due to a lack of systematic studies on treatment responses in males versus females, evidence in this area is still sparse. We argue that studies taking sex differences into account could pave the way for sex-specific and therefore personalized treatment.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Physiology

Multiple sclerosis and circadian rhythms: Can diet act as a treatment?

Olga Pivovarova-Ramich, Hanna Gwendolyn Zimmermann, Friedemann Paul

Summary: Multiple sclerosis (MS) is an autoimmune inflammatory and neurodegenerative disease of the central nervous system (CNS). Nutrition habits can influence the risk for MS, and dietary interventions may be effective in modulating MS disease course. Chronotherapeutic approaches like time-restricted eating (TRE) may benefit people with MS by stabilizing the circadian clock and restoring immunological and metabolic rhythms, thus potentially counteracting disease progression.

ACTA PHYSIOLOGICA (2023)

Article Clinical Neurology

Clinical and MRI measures to identify non-acute MOG-antibody disease in adults

Rosa Cortese, Marco Battaglini, Ferran Prados, Alessia Bianchi, Lukas Haider, Anu Jacob, Jacqueline Palace, Silvia Messina, Friedemann Paul, Jens Wuerfel, Romain Marignier, Francoise Durand-Dubief, Carolina de Medeiros Rimkus, Dagoberto Callegaro, Douglas Kazutoshi Sato, Massimo Filippi, Maria Assunta Rocca, Laura Cacciaguerra, Alex Rovira, Jaume Sastre-Garriga, Georgina Arrambide, Yaou Liu, Yunyun Duan, Claudio Gasperini, Carla Tortorella, Serena Ruggieri, Maria Pia Amato, Monica Ulivelli, Sergiu Groppa, Matthias Grothe, Sara Llufriu, Maria Sepulveda, Carsten Lukas, Barbara Bellenberg, Ruth Schneider, Piotr Sowa, Elisabeth G. Celius, Anne-Katrin Proebstel, Ozgur Yaldizli, Jannis Mueller, Bruno Stankoff, Benedetta Bodini, Luca Carmisciano, Maria Pia Sormani, Frederik Barkhof, Nicola De Stefano, Olga Ciccarelli

Summary: The study aimed to differentiate non-acute MOG-antibody disease from AQP4-neuromyelitis optica spectrum disorder and multiple sclerosis using MRI and clinical markers. The findings provide guidance for identifying patients with MOG-antibody disease in clinical practice.

BRAIN (2023)

Article Clinical Neurology

Effects of the COVID-19 Pandemic on Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Diseases COPANMO(G)-Study

Martin W. Huemmert, Franziska Buetow, Daria Tkachenko, Ilya Ayzenberg, Thivya Pakeerathan, Kerstin Hellwig, Luisa Klotz, Vivien Haeussler, Jan-Patrick Stellmann, Clemens Warnke, Yasemin Goereci, Thorleif Etgen, Felix Luessi, Paul Bronzlik, Stefan Gingele, Ann-Sophie Lauenstein, Ingo Kleiter, Paulus S. Rommer, Friedemann Paul, Judith Bellmann-Strobl, Ankelien Duchow, Florian Then Bergh, Refik Pul, Annette Walter, Hannah Pellkofer, Tania Kuempfel, Mosche Pompsch, Markus Kraemer, Philipp Albrecht, Orhan Aktas, Marius Ringelstein, Makbule Senel, Katrin Giglhuber, Achim Berthele, Sven Jarius, Brigitte Wildemann, Corinna Trebst

Summary: This study evaluated the impact of the COVID-19 pandemic on the lives of patients with NMOSD and MOGAD. It found that most patients had continued access to healthcare services and were satisfied with medical care during the pandemic. Their health-related quality of life did not decline.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2023)

Review Clinical Neurology

Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis

Sven Jarius, Orhan Aktas, Ilya Ayzenberg, Judith Bellmann-Strobl, Achim Berthele, Katrin Giglhuber, Vivien Haeussler, Joachim Havla, Kerstin W. Hellwig, Martin Huemmert, Ingo Kleiter, Luisa Klotz, Markus Krumbholz, Tania Kuempfel, Friedemann Paul, Marius Ringelstein, Klemens Ruprecht, Makbule Senel, Jan-Patrick Stellmann, Florian Then Bergh, Hayrettin Tumani, Brigitte Wildemann, Corinna Trebst

Summary: The term 'neuromyelitis optica spectrum disorders' (NMOSD) refers to aquaporin-4 immunoglobulin G (AQP4-IgG)-positive neuromyelitis optica (NMO) and related clinical syndromes without AQP4-IgG. NMOSD is distinct from multiple sclerosis (MS) in terms of pathogenesis, clinical presentation, treatment, and prognosis. Part 1 of this article series provides updated recommendations on the diagnosis and differential diagnosis of NMOSD, with a focus on distinguishing NMOSD from MS and myelin oligodendrocyte glycoprotein antibody-associated encephalomyelitis (MOG-EM). Part 2 covers treatment options for NMOSD.

JOURNAL OF NEUROLOGY (2023)

Article Clinical Neurology

Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder

Orhan Aktas, Hans-Peter Hartung, Michael A. Smith, William A. Rees, Kazuo Fujihara, Friedemann Paul, Romain Marignier, Jeffrey L. Bennett, Ho Jin Kim, Brian G. Weinshenker, Sean J. Pittock, Dean M. Wingerchuk, Gary Cutter, Dewei She, Michele Gunsior, Daniel Cimbora, Eliezer Katz, Bruce A. Cree, N-MOmentum Study Investigators

Summary: The study investigates the relationship between biomarkers (sNfL, sUCHL1, sTau, sGFAP) and disease activity/disability in NMOSD, as well as the effects of inebilizumab. Results show that sNfL is the strongest predictor of disability worsening during attacks and follow-up, and inebilizumab treatment is associated with lower levels of sGFAP and sNfL.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2023)

Article Clinical Neurology

Diagnostic value of intereye difference metrics for optic neuritis in aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorders

Frederike Cosima Oertel, Hanna G. Zimmermann, Seyedamirhosein Motamedi, Claudia Chien, Orhan Aktas, Philipp Albrecht, Marius Ringelstein, Anitha Dcunha, Lekha Pandit, Elena H. Martinez-Lapiscina, Bernardo Sanchez-Dalmau, Pablo Villoslada, Jacqueline Palace, Adriana Roca-Fernandez, Maria Isabel Leite, Srilakshmi M. Sharma, Letizia Leocani, Marco Pisa, Marta Radaelli, Marco Aurelio Lana-Peixoto, Mariana Andrade Fontenelle, Joachim Havla, Fereshteh Ashtari, Rahele Kafieh, Alireza Dehghani, Mohsen Pourazizi, Romain Marignier, Alvaro Cobo-Calvo, Nasrin Asgari, Anu Jacob, Saif Huda, Yang Mao-Draayer, Ari J. Green, Rachel Kenney, Michael R. Yeaman, Terry J. Smith, Lawrence Cook, Alexander U. Brandt, Friedemann Paul, Axel Petzold

Summary: This study evaluated the diagnostic accuracy of intereye differences (IED) in aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorders (AQP4+NMOSD) and found that IED metrics are valid parameters for the diagnosis of optic neuritis (ON) in AQP4+NMOSD.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2023)

Article Clinical Neurology

Cognition in patients with neuromyelitis optica spectrum disorders: A prospective multicentre study of 217 patients (CogniNMO-Study)

Martin W. Huemmert, Carlotta Stern, Friedemann Paul, Ankelien Duchow, Judith Bellmann-Strobl, Ilya Ayzenberg, Carolin Schwake, Ingo Kleiter, Kerstin Hellwig, Sven Jarius, Brigitte Wildemann, Makbule Senel, Achim Berthele, Katrin Giglhuber, Felix Luessi, Matthias Grothe, Luisa Klotz, Rasmus Schuelke, Stefan Gingele, Jurgen H. Faiss, Annette Walter, Clemens Warnke, Florian Then Bergh, Orhan Aktas, Marius Ringelstein, Jan-Patrick Stellmann, Vivien Haeussler, Joachim Havla, Hannah Pellkofer, Tania Kuempfel, Bruno Kopp, Corinna Trebst, Neuromyelitis Optica Study Grp

Summary: This study assessed cognitive performance in 217 NMOSD patients and found that a subset of patients showed impairment in visual processing speed and semantic fluency, regardless of antibody status. No significant changes were observed in cognitive function over a 2-year period.

MULTIPLE SCLEROSIS JOURNAL (2023)

Article Medicine, General & Internal

Structural brain changes in patients with post-COVID fatigue: a prospective observational study

Josephine Heine, Katia Schwichtenberg, Tim J. Hartung, Sophia Rekers, Claudia Chien, Fabian Boesl, Rebekka Rust, Christian Hohenfeld, Julia Bungenberg, Ana S. Costa, Carmen Scheibenbogen, Judith Bellmann-Strobl, Friedemann Paul, Christiana Franke, Kathrin Reetz, Carsten Finke

Summary: This study explores the clinical characteristics, associated structural imaging changes, and influences on fatigue severity in patients with post-COVID syndrome. The findings reveal that the fatigue experienced by these patients is associated with structural changes in the thalamus and basal ganglia, providing insights into understanding post-COVID fatigue and related neuropsychiatric complications.

ECLINICALMEDICINE (2023)

Article Clinical Neurology

Absence of self-reported neuropsychiatric and somatic symptoms after Omicron variant SARS-CoV-2 breakthrough infections

Marcel S. Woo, Christina Mayer, Thomas Theo Brehm, Gabriele Andersen, Angelika Weigel, Bernd Loewe, Ansgar W. Lohse, Marylyn M. Addo, Christian Gerloff, Johannes K. M. Knobloch, Julian Schulze zur Wiesch, Manuel A. Friese

BRAIN COMMUNICATIONS (2023)

Article Clinical Neurology

The MoxFo initiative-Mechanisms of action: Biomarkers in multiple sclerosis exercise studies

Sina C. Rosenkranz, Michelle Ploughman, Lars G. Hvid, P. Zimmer, K. Erickson, Jan-Patrick Stellmann, Diego Centonze, Manuel A. Friese

Summary: This article aims to establish recommendations for future mechanistic exercise studies in multiple sclerosis (MS) by evaluating biomarkers to decipher the underlying mechanisms of exercise in MS and improve the understanding of therapeutic approaches.

MULTIPLE SCLEROSIS JOURNAL (2023)

Review Clinical Neurology

Pathogenetic mechanisms and treatment targets in cerebral malaria

Alexandros Hadjilaou, Johannes Brandi, Mathias Riehn, Manuel A. Friese, Thomas Jacobs

Summary: Malaria is a prevalent mosquito-borne disease, and cerebral malaria is a life-threatening complication that can result in death or neurocognitive impairment. There is a critical need to develop preventive, adjunctive, and neuroprotective treatments for cerebral malaria.

NATURE REVIEWS NEUROLOGY (2023)

Article Medicine, Research & Experimental

iPSC-derived reactive astrocytes from patients with multiple sclerosis protect cocultured neurons in inflammatory conditions

Janis Kerkering, Bakhrom Muinjonov, Kamil S. Rosiewicz, Sebastian Diecke, Charlotte Biese, Juliane Schiweck, Claudia Chien, Dario Zocholl, Thomas Conrad, Friedemann Paul, Marlen Alisch, Volker Siffrin

Summary: Multiple sclerosis (MS) is a common chronic central nervous system inflammatory disease with variable clinical courses. Researchers investigated the mechanisms in benign MS (BMS) compared with progressive MS (PMS) using induced pluripotent stem cells (iPSCs). They found that BMS astrocytes exhibited less axonal damage and upregulated neuronal resilience pathways, accompanied by differential growth factor expression. Furthermore, cocultures of BMS astrocytes and neurons showed neuroprotective effects against inflammatory-induced neurite damage through the expression of specific growth factors and JAK-STAT activation.

JOURNAL OF CLINICAL INVESTIGATION (2023)

Article Clinical Neurology

Increased flexibility of brain dynamics in patients with multiple sclerosis

Nina von Schwanenflug, Stefan P. Koch, Stephan Krohn, Tommy A. A. Broeders, David M. Lydon-Staley, Dani S. Bassett, Menno M. Schoonheim, Friedemann Paul, Carsten Finke

Summary: By applying a time-resolved graph-analytical framework, this study identifies a hyperflexible reorganization of brain activity in multiple sclerosis, characterized by increased global flexibility, promiscuity, entropy, and cohesion. This functional reorganization is linked to clinical disability, suggesting the importance of multilayer temporal dynamics in the manifestation of multiple sclerosis.

BRAIN COMMUNICATIONS (2023)

Article Radiology, Nuclear Medicine & Medical Imaging

Accelerated Simultaneous T2 and T2* Mapping of Multiple Sclerosis Lesions Using Compressed Sensing Reconstruction of Radial RARE-EPI MRI

Carl J. J. Herrmann, Ludger Starke, Jason M. Millward, Joseph Kuchling, Friedemann Paul, Thoralf Niendorf

Summary: Accelerated T-2 and T-2* mapping using highly undersampled 2in1-RARE-EPI with compressed sensing (CS) reconstruction is feasible. The results show that for R-extra = 6, the overall MAPE for T-2* is <= 8% and <= 4% for T-2; for R-extra = 12, the overall MAPE is <13% for T-2* and <5% for T-2.

TOMOGRAPHY (2023)

Article Medicine, Research & Experimental

First in vivo fluorine-19 magnetic resonance imaging of the multiple sclerosis drug siponimod

Ludger Starke, Jason M. Millward, Christian Prinz, Fatima Sherazi, Helmar Waiczies, Christoph Lippert, Marc Nazare, Friedemann Paul, Thoralf Niendorf, Sonia Waiczies

Summary: The study demonstrates that siponimod can be imaged non-invasively using 19F UTE MRI, laying the foundation for further preclinical and clinical investigations. This technique provides an accurate understanding of the distribution of CNS-acting drugs in individual patients, which can contribute to personalized therapy.

THERANOSTICS (2023)

No Data Available